JP2015508096A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508096A5 JP2015508096A5 JP2014558256A JP2014558256A JP2015508096A5 JP 2015508096 A5 JP2015508096 A5 JP 2015508096A5 JP 2014558256 A JP2014558256 A JP 2014558256A JP 2014558256 A JP2014558256 A JP 2014558256A JP 2015508096 A5 JP2015508096 A5 JP 2015508096A5
- Authority
- JP
- Japan
- Prior art keywords
- trifluoromethyl
- amino
- bipyrimidinyl
- morpholin
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 16
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000034578 Multiple myelomas Diseases 0.000 claims 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 3
- 206010038389 Renal cancer Diseases 0.000 claims 3
- 206010039491 Sarcoma Diseases 0.000 claims 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 210000004100 adrenal gland Anatomy 0.000 claims 3
- 201000005188 adrenal gland cancer Diseases 0.000 claims 3
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 3
- 210000000481 breast Anatomy 0.000 claims 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 3
- 210000001072 colon Anatomy 0.000 claims 3
- 208000029742 colonic neoplasm Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 210000003238 esophagus Anatomy 0.000 claims 3
- 206010017758 gastric cancer Diseases 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- 201000010982 kidney cancer Diseases 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 201000007270 liver cancer Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 210000001672 ovary Anatomy 0.000 claims 3
- 210000000496 pancreas Anatomy 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 210000002307 prostate Anatomy 0.000 claims 3
- 206010038038 rectal cancer Diseases 0.000 claims 3
- 210000000664 rectum Anatomy 0.000 claims 3
- 201000001275 rectum cancer Diseases 0.000 claims 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 3
- 210000002784 stomach Anatomy 0.000 claims 3
- 201000011549 stomach cancer Diseases 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 201000002510 thyroid cancer Diseases 0.000 claims 3
- 210000003932 urinary bladder Anatomy 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 210000001215 vagina Anatomy 0.000 claims 3
- 206010046885 vaginal cancer Diseases 0.000 claims 3
- 208000013139 vaginal neoplasm Diseases 0.000 claims 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 2
- -1 2′-amino-2-morpholino-4 ′-(trifluoromethyl)-[4,5′-bipyrimidin] -6-yl Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- CUZHYMLWMBVXNZ-NEPJUHHUSA-N (3ar,6ar)-3-[6-[2-amino-4-(trifluoromethyl)pyrimidin-5-yl]-2-morpholin-4-ylpyrimidin-4-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]oxazol-2-one Chemical compound FC(F)(F)C1=NC(N)=NC=C1C1=CC(N2C(O[C@H]3COC[C@H]32)=O)=NC(N2CCOCC2)=N1 CUZHYMLWMBVXNZ-NEPJUHHUSA-N 0.000 claims 1
- YDFWDRYMAKYLOY-YRGRVCCFSA-N (3ar,6r,6ar)-3-[6-[2-amino-4-(trifluoromethyl)pyrimidin-5-yl]-2-morpholin-4-ylpyrimidin-4-yl]-6-hydroxy-4,5,6,6a-tetrahydro-3ah-cyclopenta[d][1,3]oxazol-2-one Chemical compound FC(F)(F)C1=NC(N)=NC=C1C1=CC(N2C(O[C@H]3[C@H](O)CC[C@H]32)=O)=NC(N2CCOCC2)=N1 YDFWDRYMAKYLOY-YRGRVCCFSA-N 0.000 claims 1
- YDFWDRYMAKYLOY-OBJOEFQTSA-N (3as,6s,6as)-3-[6-[2-amino-4-(trifluoromethyl)pyrimidin-5-yl]-2-morpholin-4-ylpyrimidin-4-yl]-6-hydroxy-4,5,6,6a-tetrahydro-3ah-cyclopenta[d][1,3]oxazol-2-one Chemical compound FC(F)(F)C1=NC(N)=NC=C1C1=CC(N2C(O[C@@H]3[C@@H](O)CC[C@@H]32)=O)=NC(N2CCOCC2)=N1 YDFWDRYMAKYLOY-OBJOEFQTSA-N 0.000 claims 1
- RAFZQDWSGKEORO-QGZVFWFLSA-N (4r)-3-[6-[2-amino-4-(trifluoromethyl)pyrimidin-5-yl]-2-morpholin-4-ylpyrimidin-4-yl]-4-(hydroxymethyl)-4-methyl-1,3-oxazolidin-2-one Chemical compound OC[C@]1(C)COC(=O)N1C1=CC(C=2C(=NC(N)=NC=2)C(F)(F)F)=NC(N2CCOCC2)=N1 RAFZQDWSGKEORO-QGZVFWFLSA-N 0.000 claims 1
- RAFZQDWSGKEORO-KRWDZBQOSA-N (4s)-3-[6-[2-amino-4-(trifluoromethyl)pyrimidin-5-yl]-2-morpholin-4-ylpyrimidin-4-yl]-4-(hydroxymethyl)-4-methyl-1,3-oxazolidin-2-one Chemical compound OC[C@@]1(C)COC(=O)N1C1=CC(C=2C(=NC(N)=NC=2)C(F)(F)F)=NC(N2CCOCC2)=N1 RAFZQDWSGKEORO-KRWDZBQOSA-N 0.000 claims 1
- BRPIFAODBNJVGK-GXFFZTMASA-N (4s,5r)-3-[6-[2-amino-4-(trifluoromethyl)pyrimidin-5-yl]-2-morpholin-4-ylpyrimidin-4-yl]-5-(2-hydroxyethyl)-4-methyl-1,3-oxazolidin-2-one Chemical compound C[C@H]1[C@@H](CCO)OC(=O)N1C1=CC(C=2C(=NC(N)=NC=2)C(F)(F)F)=NC(N2CCOCC2)=N1 BRPIFAODBNJVGK-GXFFZTMASA-N 0.000 claims 1
- RAFZQDWSGKEORO-UHFFFAOYSA-N 3-[6-[2-amino-4-(trifluoromethyl)pyrimidin-5-yl]-2-morpholin-4-ylpyrimidin-4-yl]-4-(hydroxymethyl)-4-methyl-1,3-oxazolidin-2-one Chemical compound OCC1(C)COC(=O)N1C1=CC(C=2C(=NC(N)=NC=2)C(F)(F)F)=NC(N2CCOCC2)=N1 RAFZQDWSGKEORO-UHFFFAOYSA-N 0.000 claims 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000007962 solid dispersion Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261602954P | 2012-02-24 | 2012-02-24 | |
| US61/602,954 | 2012-02-24 | ||
| US201261736707P | 2012-12-13 | 2012-12-13 | |
| US61/736,707 | 2012-12-13 | ||
| PCT/IB2013/051443 WO2013124826A1 (en) | 2012-02-24 | 2013-02-22 | Oxazolidin- 2 -one compounds and uses thereof as pi3ks inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508096A JP2015508096A (ja) | 2015-03-16 |
| JP2015508096A5 true JP2015508096A5 (https=) | 2016-04-21 |
| JP6154404B2 JP6154404B2 (ja) | 2017-06-28 |
Family
ID=48142031
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558256A Active JP6154404B2 (ja) | 2012-02-24 | 2013-02-22 | オキサゾリジン−２−オン化合物およびｐｉ３ｋ阻害剤としてのその使用 |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8865894B2 (https=) |
| EP (1) | EP2817307B1 (https=) |
| JP (1) | JP6154404B2 (https=) |
| KR (1) | KR101640698B1 (https=) |
| CN (1) | CN104144926B (https=) |
| AP (1) | AP2014007835A0 (https=) |
| AR (1) | AR090121A1 (https=) |
| AU (1) | AU2013223713C1 (https=) |
| BR (1) | BR112014020672B1 (https=) |
| CA (1) | CA2865372A1 (https=) |
| CO (1) | CO7051028A2 (https=) |
| CR (1) | CR20140397A (https=) |
| DO (1) | DOP2014000194A (https=) |
| EA (1) | EA026031B1 (https=) |
| ES (1) | ES2598118T3 (https=) |
| GE (1) | GEP20156389B (https=) |
| GT (1) | GT201400178A (https=) |
| HK (1) | HK1199643A1 (https=) |
| IL (1) | IL233936A (https=) |
| MX (1) | MX353341B (https=) |
| NI (1) | NI201400089A (https=) |
| NZ (1) | NZ629198A (https=) |
| PE (1) | PE20142456A1 (https=) |
| PH (1) | PH12014501900A1 (https=) |
| PL (1) | PL2817307T3 (https=) |
| PT (1) | PT2817307T (https=) |
| SG (1) | SG11201404794XA (https=) |
| TW (1) | TW201339155A (https=) |
| UY (1) | UY34632A (https=) |
| WO (1) | WO2013124826A1 (https=) |
| ZA (1) | ZA201405446B (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014007310A2 (pt) | 2011-09-27 | 2017-04-04 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| JP6404217B2 (ja) * | 2012-09-11 | 2018-10-10 | メディベイション プロステイト セラピューティクス エルエルシー | エンザルタミドの製剤 |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| JP6387360B2 (ja) | 2013-03-14 | 2018-09-05 | ノバルティス アーゲー | 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| HUE045065T2 (hu) | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| MX373444B (es) | 2014-03-24 | 2020-04-30 | Novartis Ag | Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas. |
| TW201609108A (zh) | 2014-07-25 | 2016-03-16 | 諾華公司 | 醫藥劑型 |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| ES2807785T3 (es) | 2014-10-22 | 2021-02-24 | Bristol Myers Squibb Co | Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k |
| EP3209665B1 (en) | 2014-10-22 | 2019-08-14 | Bristol-Myers Squibb Company | Substituted pyrrolotriazine amine compounds as pi3k inhibitors |
| EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
| EA035817B1 (ru) | 2015-03-10 | 2020-08-14 | Адуро Байотек, Инк. | Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона" |
| AU2016287463B2 (en) * | 2015-07-02 | 2020-07-02 | F. Hoffmann-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
| CN111848643A (zh) * | 2015-07-02 | 2020-10-30 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| HRP20211058T8 (hr) | 2015-07-29 | 2021-11-26 | Novartis Ag | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 |
| PE20181326A1 (es) | 2015-11-03 | 2018-08-20 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| EA201991069A1 (ru) * | 2016-11-02 | 2019-10-31 | Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом | |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| MY204117A (en) | 2017-06-22 | 2024-08-08 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| US11919902B2 (en) | 2017-12-22 | 2024-03-05 | Hibercell, Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| TWI869346B (zh) | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| CN109134558A (zh) * | 2018-09-21 | 2019-01-04 | 常州方圆制药有限公司 | 一种提高1-N-乙基庆大霉素Cla收率的合成方法 |
| CN109970764B (zh) * | 2019-03-26 | 2021-11-09 | 上海吉奉生物科技有限公司 | 一种（S）-1,1,5,5-四甲基二氢恶唑并[3,4-c]恶唑-3-酮的合成方法 |
| CN114502590A (zh) | 2019-09-18 | 2022-05-13 | 诺华股份有限公司 | Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法 |
Family Cites Families (124)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB581334A (en) | 1943-09-29 | 1946-10-09 | Francis Henry Swinden Curd | New pyrimidine compounds |
| JPS4921148Y1 (https=) | 1970-02-07 | 1974-06-06 | ||
| JPS4921149Y1 (https=) | 1970-06-27 | 1974-06-06 | ||
| JPS4921148B1 (https=) | 1970-12-28 | 1974-05-30 | ||
| JPS4921149B1 (https=) | 1970-12-28 | 1974-05-30 | ||
| DE2341925A1 (de) | 1973-08-20 | 1975-03-06 | Thomae Gmbh Dr K | Neue pyrimidinderivate und verfahren zu ihrer herstellung |
| AT340933B (de) | 1973-08-20 | 1978-01-10 | Thomae Gmbh Dr K | Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze |
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| US4994386A (en) | 1987-07-13 | 1991-02-19 | Pharmacia Diagnostics, Inc. | Production of HBLV virus in the HSB-2 cell line |
| US4929726A (en) | 1988-02-09 | 1990-05-29 | Georgia State University Foundation, Inc. | Novel diazines and their method of preparation |
| EP0330263A1 (en) | 1988-02-25 | 1989-08-30 | Merck & Co. Inc. | Piperazinylalkylpyrimidines as hypoglycemic agents |
| GB9012311D0 (en) | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| CA2065443A1 (en) | 1990-07-03 | 1992-01-04 | Akira Mizuchi | Pyrimidine compound and pharmaceutically acceptable salts thereof |
| KR100275300B1 (ko) | 1995-04-13 | 2000-12-15 | 고바야시 유키오 | 신규 4,6-디아릴피리미딘 유도체 및 그 염(novel 4,6-diarylpyrimidine derivatives and salts thereof) |
| JP3734907B2 (ja) | 1996-12-19 | 2006-01-11 | 富士写真フイルム株式会社 | 現像処理方法 |
| CN1129597C (zh) | 1997-07-24 | 2003-12-03 | 全药工业株式会社 | 杂环化合物和以其为有效成分的抗肿瘤剂 |
| JPH11158073A (ja) | 1997-09-26 | 1999-06-15 | Takeda Chem Ind Ltd | アデノシンａ３拮抗剤 |
| US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
| US6150362A (en) | 1997-12-12 | 2000-11-21 | Henkin; Jack | Triazine angiogenesis inhibitors |
| EP0930302B1 (en) | 1998-01-16 | 2003-04-02 | F.Hoffmann-La Roche Ag | Benzosulfone derivatives |
| WO1999065897A1 (en) | 1998-06-19 | 1999-12-23 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| CA2359680A1 (en) | 1999-01-22 | 2000-07-27 | David M. Armistead | Kinase inhibitors |
| US6495558B1 (en) | 1999-01-22 | 2002-12-17 | Amgen Inc. | Kinase inhibitors |
| EP1206260A4 (en) | 1999-06-30 | 2002-10-30 | Merck & Co Inc | SRC-KINASE INHIBITING COMPOUNDS |
| WO2001000213A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| EP1194152A4 (en) | 1999-06-30 | 2002-11-06 | Merck & Co Inc | Links to SRC kinase inhibition |
| AU777735B2 (en) | 1999-07-15 | 2004-10-28 | Pharmacopeia, Inc. | Bradykinin B1 receptor antagonists |
| JP2001089452A (ja) | 1999-09-22 | 2001-04-03 | Sankyo Co Ltd | ピリミジン誘導体 |
| AU3704101A (en) | 2000-02-17 | 2001-08-27 | Amgen Inc | Kinase inhibitors |
| CN100355751C (zh) | 2000-03-29 | 2007-12-19 | 西克拉塞尔有限公司 | 2－取代的4－杂芳基－嘧啶、其组合物及其用途 |
| KR100774855B1 (ko) | 2000-04-27 | 2007-11-08 | 아스텔라스세이야쿠 가부시키가이샤 | 축합 헤테로아릴 유도체 |
| CN1657523A (zh) | 2000-04-28 | 2005-08-24 | 田边制药株式会社 | 环状化合物 |
| WO2002000647A1 (en) | 2000-06-23 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
| AU9502601A (en) | 2000-09-06 | 2002-03-22 | Chiron Corp | Inhibitors of glycogen synthase kinase 3 |
| WO2002022605A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| SE0004053D0 (sv) | 2000-11-06 | 2000-11-06 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
| US6989385B2 (en) | 2000-12-21 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002062766A2 (en) | 2001-02-07 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| AU2002258400A1 (en) | 2001-02-16 | 2002-08-28 | Tularik Inc. | Methods of using pyrimidine-based antiviral agents |
| EP1395561A1 (en) | 2001-05-25 | 2004-03-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Carbamate and oxamide compounds as inhibitors of cytokine production |
| CA2450934A1 (en) | 2001-06-19 | 2002-12-27 | Marco Dodier | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
| US6603000B2 (en) | 2001-07-11 | 2003-08-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Synthesis for heteroarylamine compounds |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| EP1485381B8 (en) | 2002-03-15 | 2010-05-12 | Vertex Pharmaceuticals Incorporated | Azolylaminoazine as inhibitors of protein kinases |
| US20040009981A1 (en) | 2002-03-15 | 2004-01-15 | David Bebbington | Compositions useful as inhibitors of protein kinases |
| US6846928B2 (en) | 2002-03-15 | 2005-01-25 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| DE60332433D1 (de) | 2002-03-15 | 2010-06-17 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
| US20040082627A1 (en) | 2002-06-21 | 2004-04-29 | Darrow James W. | Certain aromatic monocycles as kinase modulators |
| DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
| JP2006510597A (ja) | 2002-09-27 | 2006-03-30 | メルク エンド カムパニー インコーポレーテッド | 置換ピリミジン類 |
| US20040171073A1 (en) | 2002-10-08 | 2004-09-02 | Massachusetts Institute Of Technology | Compounds for modulation of cholesterol transport |
| US7223870B2 (en) | 2002-11-01 | 2007-05-29 | Pfizer Inc. | Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction |
| EA013811B1 (ru) | 2002-11-21 | 2010-08-30 | Новартис Вэксинес Энд Дайэгностикс, Инк. | 2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака |
| JP2006521357A (ja) | 2003-03-24 | 2006-09-21 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャンネル遮断薬としてのビアリール置換６員複素環化合物 |
| US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
| JP4895806B2 (ja) | 2003-04-09 | 2012-03-14 | エクセリクシス， インク． | Ｔｉｅ−２モジュレータと使用方法 |
| WO2005002514A2 (en) | 2003-06-13 | 2005-01-13 | Echelon Biosciences Incorporated | Compounds having inhibitibe activity of phosphatidylinositol 3-kinase and methods of use thereof |
| CA2531490A1 (en) | 2003-07-15 | 2005-02-03 | Neurogen Corporation | Substituted pyrimidin-4-ylamina analogues as vanilloid receptor ligands |
| CA2531619A1 (en) | 2003-07-16 | 2005-01-27 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
| CA2561895A1 (en) | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
| GB0415365D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
| MY145822A (en) | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
| JP2008521900A (ja) | 2004-11-30 | 2008-06-26 | アムジエン・インコーポレーテツド | キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用 |
| WO2006065872A1 (en) | 2004-12-13 | 2006-06-22 | Neurogen Corporation | Piperazinyl-pyridine analogues |
| CA2590586A1 (en) | 2004-12-13 | 2006-07-06 | Neurogen Corporation | Substituted biaryl analogues |
| ES2382068T3 (es) | 2004-12-28 | 2012-06-05 | Kinex Pharmaceuticals, Llc | Composiciones y métodos para tratar trastornos de proliferación celular |
| WO2006078992A2 (en) | 2005-01-19 | 2006-07-27 | Neurogen Corporation | Heteroaryl substituted piperazinyl-pyridine analogues |
| CA2599320A1 (en) | 2005-02-25 | 2006-08-31 | Kudos Pharmaceuticals Limited | Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents |
| TW200716594A (en) | 2005-04-18 | 2007-05-01 | Neurogen Corp | Substituted heteroaryl CB1 antagonists |
| US7930013B2 (en) | 2005-06-29 | 2011-04-19 | Compumedics Limited | Sensor assembly with conductive bridge |
| GB2431156A (en) | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
| EP1979325A1 (en) | 2006-01-11 | 2008-10-15 | AstraZeneca AB | Morpholino pyrimidine derivatives and their use in therapy |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| EP2012794B1 (en) * | 2006-04-13 | 2014-09-17 | The Trustees of Columbia University in the City of New York | Compositions and intraluminal devices for inhibiting vascular stenosis |
| TW200833342A (en) | 2006-12-28 | 2008-08-16 | Basf Ag | 2-substituted pyrimidines I in therapy |
| WO2008098058A1 (en) | 2007-02-06 | 2008-08-14 | Novartis Ag | Pi 3-kinase inhibitors and methods of their use |
| US7957951B2 (en) | 2007-03-16 | 2011-06-07 | Robert Bosch Gmbh | Address translation system for use in a simulation environment |
| AU2008273889B2 (en) | 2007-07-09 | 2012-03-08 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
| WO2009066084A1 (en) * | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
| US20110033453A1 (en) | 2008-03-05 | 2011-02-10 | Carlos Garcia-Echeverria | Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members |
| KR20100126553A (ko) | 2008-03-26 | 2010-12-01 | 노파르티스 아게 | Ｖｅｇｆ-유도성 혈관신생 과정의 유력한 조절제로서의 이미다조퀴놀린 및 피리미딘 유도체 |
| JP2011515462A (ja) | 2008-03-27 | 2011-05-19 | アウククランド ウニセルビセス リミテッド | 置換されたピリミジン、及びトリアジン、並びに癌療法におけるこれらの使用 |
| TW200948362A (en) | 2008-04-09 | 2009-12-01 | Mitsubishi Tanabe Pharma Corp | New compounds and their uses |
| GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| WO2010049481A1 (en) | 2008-10-31 | 2010-05-06 | Novartis Ag | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| US8513242B2 (en) | 2008-12-12 | 2013-08-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| US8673891B2 (en) | 2009-02-06 | 2014-03-18 | Nippon Shinyaku Co., Ltd. | Aminopyrazine derivative and medicine |
| JP5747440B2 (ja) | 2009-02-06 | 2015-07-15 | 住友化学株式会社 | ヒドラジド化合物及びその有害生物防除用途 |
| US20120121515A1 (en) | 2009-03-13 | 2012-05-17 | Lenny Dang | Methods and compositions for cell-proliferation-related disorders |
| WO2010120994A2 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis |
| MX2011012343A (es) | 2009-05-19 | 2011-12-14 | Dow Agrosciences Llc | Compuestos y metodos para controlar hongos. |
| CA2767008C (en) | 2009-07-07 | 2018-01-30 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| WO2011017296A1 (en) | 2009-08-04 | 2011-02-10 | Schering Corporation | 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
| AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
| JP2013504325A (ja) | 2009-09-09 | 2013-02-07 | アビラ セラピューティクス， インコーポレイテッド | Ｐｉ３キナーゼインヒビターおよびその使用 |
| ES2642109T3 (es) | 2009-12-09 | 2017-11-15 | Agios Pharmaceuticals, Inc. | Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH |
| GB201004200D0 (en) | 2010-03-15 | 2010-04-28 | Univ Basel | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| WO2011143160A2 (en) | 2010-05-10 | 2011-11-17 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| CN103097340B (zh) | 2010-07-16 | 2018-03-16 | 安吉奥斯医药品有限公司 | 治疗活性组合物及其使用方法 |
| SG188439A1 (en) | 2010-10-01 | 2013-05-31 | Novartis Ag | Manufacturing process for pyrimidine derivatives |
| SG189019A1 (en) | 2010-10-18 | 2013-05-31 | Cerenis Therapeutics Holding Sa | Compounds, compositions and methods useful for cholesterol mobilisation |
| GB201106829D0 (en) | 2011-04-21 | 2011-06-01 | Proximagen Ltd | Heterocyclic compounds |
| EP2673268A1 (en) | 2011-02-11 | 2013-12-18 | Dana-Farber Cancer Institute, Inc. | Method of inhibiting hamartoma tumor cells |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| WO2013030368A1 (en) | 2011-09-01 | 2013-03-07 | Novartis Ag | Pi3k inhibitor for use in the treatment of bone cancer or for preventing metastatic dissemination primary cancer cells into the bone |
| BR112014007310A2 (pt) | 2011-09-27 | 2017-04-04 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante |
| AU2012318874A1 (en) | 2011-10-06 | 2014-05-15 | Merck Sharp & Dohme Corp. | 1,3-substituted azetidine PDE10 inhibitors |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| WO2013173283A1 (en) | 2012-05-16 | 2013-11-21 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
| RU2014154009A (ru) | 2012-06-06 | 2016-08-10 | Новартис Аг | Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания |
| WO2014028566A1 (en) | 2012-08-16 | 2014-02-20 | Novartis Ag | Combination of pi3k inhibitor and c-met inhibitor |
| AU2013336807B2 (en) | 2012-10-23 | 2016-10-27 | Novartis Ag | Improved process for manufacturing 5-(2,6-Di-4-morpholinyl-4-pyrimidinyl)-4-trifluoromethylpyridin-2-amine |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| JP6387360B2 (ja) | 2013-03-14 | 2018-09-05 | ノバルティス アーゲー | 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン |
| CN103483345B (zh) | 2013-09-25 | 2016-07-06 | 中山大学 | Pi3k激酶抑制剂、包含其的药物组合物及其应用 |
| CN103694218B (zh) | 2013-12-05 | 2016-04-27 | 中山大学 | 嘧啶化合物、pi3k抑制剂、包含pi3k抑制剂的药物组合物及应用 |
-
2013
- 2013-02-21 UY UY0001034632A patent/UY34632A/es not_active Application Discontinuation
- 2013-02-22 AR ARP130100536A patent/AR090121A1/es unknown
- 2013-02-22 AU AU2013223713A patent/AU2013223713C1/en active Active
- 2013-02-22 PE PE2014001291A patent/PE20142456A1/es not_active Application Discontinuation
- 2013-02-22 BR BR112014020672-4A patent/BR112014020672B1/pt active IP Right Grant
- 2013-02-22 NZ NZ629198A patent/NZ629198A/en not_active IP Right Cessation
- 2013-02-22 CA CA2865372A patent/CA2865372A1/en not_active Abandoned
- 2013-02-22 US US13/773,947 patent/US8865894B2/en active Active
- 2013-02-22 KR KR1020147023243A patent/KR101640698B1/ko active Active
- 2013-02-22 EP EP13717317.5A patent/EP2817307B1/en active Active
- 2013-02-22 EA EA201491579A patent/EA026031B1/ru not_active IP Right Cessation
- 2013-02-22 TW TW102106331A patent/TW201339155A/zh unknown
- 2013-02-22 MX MX2014010141A patent/MX353341B/es active IP Right Grant
- 2013-02-22 HK HK15100012.7A patent/HK1199643A1/xx unknown
- 2013-02-22 WO PCT/IB2013/051443 patent/WO2013124826A1/en not_active Ceased
- 2013-02-22 PT PT137173175T patent/PT2817307T/pt unknown
- 2013-02-22 SG SG11201404794XA patent/SG11201404794XA/en unknown
- 2013-02-22 AP AP2014007835A patent/AP2014007835A0/xx unknown
- 2013-02-22 ES ES13717317.5T patent/ES2598118T3/es active Active
- 2013-02-22 GE GEAP201313557A patent/GEP20156389B/en unknown
- 2013-02-22 CN CN201380010698.9A patent/CN104144926B/zh active Active
- 2013-02-22 PL PL13717317T patent/PL2817307T3/pl unknown
- 2013-02-22 JP JP2014558256A patent/JP6154404B2/ja active Active
-
2014
- 2014-07-23 ZA ZA2014/05446A patent/ZA201405446B/en unknown
- 2014-08-04 IL IL233936A patent/IL233936A/en not_active IP Right Cessation
- 2014-08-12 NI NI201400089A patent/NI201400089A/es unknown
- 2014-08-15 CO CO14179492A patent/CO7051028A2/es unknown
- 2014-08-22 PH PH12014501900A patent/PH12014501900A1/en unknown
- 2014-08-22 CR CR20140397A patent/CR20140397A/es unknown
- 2014-08-22 GT GT201400178A patent/GT201400178A/es unknown
- 2014-08-22 DO DO2014000194A patent/DOP2014000194A/es unknown
- 2014-09-05 US US14/478,523 patent/US9458177B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015508096A5 (https=) | ||
| ES2830279T3 (es) | Cromanos sustituidos y método de uso | |
| ES2963695T3 (es) | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidin-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteína con dedos de zinc 2 de la familia ikaros (ikzf2) | |
| ES2784454T3 (es) | Aril éteres y usos de los mismos | |
| ES2757948T3 (es) | Compuestos heterocíclicos como inhibidores LSD1 | |
| ES3042546T3 (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| ES2952332T3 (es) | Compuestos espirocíclicos y sus métodos de preparación y uso | |
| RU2018103944A (ru) | Производные этинила как модуляторы метаботропного рецептора глутамата | |
| ES2910071T3 (es) | Compuestos de aminopirazina diol como inhibidores de PI3K-Y | |
| CN103102342B (zh) | 氨基喹唑啉类衍生物及其盐和使用方法 | |
| JP2022510501A (ja) | 化合物、医薬組成物、ならびに化合物の調製方法及びａｔｒキナーゼ阻害剤としてのその使用方法 | |
| ES2814151T3 (es) | 1-Ciclohexilo-2-fenilaminobenzimidazoles como inhibidores de MIDH1 para el tratamiento de tumores | |
| JP2019513743A (ja) | インドールアミン ２，３−ジオキシゲナーゼ阻害剤、その製造方法及び応用 | |
| KR20180063895A (ko) | 단백질 키나제 억제제로서의 벤조락탐 화합물 | |
| RU2018114518A (ru) | Новые бициклические соединения в качестве двойных ингибиторов аутотаксина (atx)/карбоангидразы (ca) | |
| JP2013535491A5 (https=) | ||
| ES2639402T3 (es) | 2,3-dihidroimidazo[1,2-c]quinolinas sustituidas con arilaminoalcohol | |
| CN115605479A (zh) | 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| SI3027602T1 (en) | New indole and pyrrole derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| JP2013510123A5 (https=) | ||
| RU2013106754A (ru) | Производное фталазинонкетона, способ его получения и его фармацевтическое применение | |
| JP2009514870A5 (https=) | ||
| ME02838B (me) | 3,4-dihidroizokinolin-2(1h)-ilni spojevi | |
| ES2825348T3 (es) | Compuestos y composición farmacéutica asociados al sistema ubiquitinación-proteasoma | |
| RU2017118165A (ru) | Ингибиторы энхансера гомолога 2 zestes |